{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007578","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.421877+00:00","generated_at":"2026-06-18T04:24:01.880120+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sight Sciences Q4 2022 revenue up 40% YoY to $20.5M; guides 2023 revenue $89-94M","bullets":["Full-year 2022 revenue $71.3M (+46% YoY); Surgical Glaucoma $65.6M (+41%), Dry Eye $5.7M (+133%).","Q4 2022 net loss $16.9M ($0.35/share) vs $15.9M loss ($0.34/share) in Q4 2021.","Q4 2022 operating expenses $33.9M, down 10% sequentially from Q3 2022.","OMNI facilities reached 941 and TearCare facilities grew to 1,042 as of Dec 31, 2022.","2023 revenue guidance $89M-$94M, representing 25%-32% growth over 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007578","json":"https://secwatch.observer/filing/0000950170-23-007578.json","markdown":"https://secwatch.observer/filing/0000950170-23-007578.md","text":"https://secwatch.observer/filing/0000950170-23-007578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023007578/0000950170-23-007578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023007578/sght-20230313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:24:01.880120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"11cf738f587fc0e3f139bbefde87188bd02fc8bd","claim":"Sight Sciences, Inc. updated its year ending December 31, 2023 guidance (initiated).","evidence_excerpt":"Sight Sciences, Inc. (the \"Company\") issued a press release announcing its financial results for the four quarter and year ended December 31, 2022 and providing guidance for the year ending December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023007578/0000950170-23-007578-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ending December 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"17659c9a2e9852db0ac313c9aa717d670f37ce8e","claim":"Sight Sciences, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $20.5 million, net income $16.9 million, EPS $0.35 per share.","evidence_excerpt":"31, 2023. Recent Financial Highlights • Generated 2022 total revenue of $71.3 million, an increase of 46% compared to 2021 • Generated fourth quarter 2022 total revenue of $20.5 million, an increase of 40% compared to the prior year period • Reduced fourth quarter 2022 operating expenses by $3.7 million versus the third quarter of 2022 • Improved total gross","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023007578/0000950170-23-007578-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$20.5 million"},{"label":"Net income","value":"$16.9 million"},{"label":"EPS","value":"$0.35 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c19eb73bcd9dd87df540c83ffabe2a05332558fb","claim":"Sight Sciences, Inc. reported the year ended December 31, 2022 results: revenue $71.3 million, net income $86.2 million, EPS $1.80 per share.","evidence_excerpt":"quarter and year ended December 31, 2022 and issued financial guidance for the year ending December 31, 2023. Recent Financial Highlights • Generated 2022 total revenue of $71.3 million, an increase of 46% compared to 2021 • Generated fourth quarter 2022 total revenue of $20.5 million, an increase of 40% compared to the prior year period • Reduced fourth quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023007578/0000950170-23-007578-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$71.3 million"},{"label":"Net income","value":"$86.2 million"},{"label":"EPS","value":"$1.80 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}